In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wallace

Executive Editor

Generics Bulletin Executive Editor Dave Wallace has more than 10 years' experience of reporting on the global generics, biosimilars and value-added medicines industries. Having begun his career in the European chemicals industry, Dave has now spent over a decade with Generics Bulletin, becoming editor from 2018. Bringing his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Award.

Latest From David Wallace

Advanz Claims A First With German Lanreotide Launch

Advanz has claimed a first with a European launch of a rival to Ipsen’s Somatuline, introducing its generic lanreotide in Germany under the name Mytolac.

Launches Generic Drugs

Pressure Grows To Solve Northern Ireland Supply Issues

As political tensions between the UK and EU mount over the Northern Ireland Protocol instigated as part of the pair’s Brexit agreement, the off-patent industry is growing increasingly concerned that regulatory uncertainty will put supply at risk.

United Kingdom Europe

Sorrento And Mabpharm Get ‘Biobetter’ Infliximab Approval In China

Sorrento and Mabpharm have revealed plans to take their infliximab “biobetter” global, after China’s NMPA approved the product, which has an improved safety profile compared to Remicade.

Biosimilars Value-Added Medicines

Pfizer And J&J Settle Remicade Antitrust Litigation

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

Deals Legal Issues

EU, Indian And US Leaders Share Global Outlook To 2030

At an IGBA panel discussion moderated by Generics Bulletin’s editor, three industry leaders representing Europe, India and the US debated the key issues facing the international off-patent sector today.

Generic Drugs Biosimilars

Teva Reshuffles Top Management

Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.

Appointments Strategy
See All
UsernamePublicRestriction

Register